{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:30Z","timestamp":1793228250307,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Arab Journal of Gastroenterology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ajg.2024.07.003","type":"journal-article","created":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T10:51:30Z","timestamp":1721559090000},"page":"299-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of IBD disease activity by Interleukin-6 and serum amyloid A in relation with fecal calprotectin and endoscopic indices"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-0536","authenticated-orcid":false,"given":"Ahmed","family":"Bahaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Elbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Elmakhzangy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Abd El-Kareem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AbdelAziz","family":"Gaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed B.","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maissa","family":"El Raziky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajg.2024.07.003_b0005","doi-asserted-by":"crossref","first-page":"11246","DOI":"10.3748\/wjg.v21.i40.11246","article-title":"Disease monitoring in inflammatory bowel disease","volume":"21","author":"Chang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ajg.2024.07.003_b0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00535-018-1439-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease","volume":"53","author":"Matsuoka","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ajg.2024.07.003_b0015","doi-asserted-by":"crossref","unstructured":"Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn\u2019s disease: what the clinician needs to know. Therap Adv Gastroenterol 2019;12:1756284819856865. https:\/\/doi.org\/10.1177\/1756284819856865.","DOI":"10.1177\/1756284819856865"},{"key":"10.1016\/j.ajg.2024.07.003_b0020","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/ibd\/izaa210","article-title":"Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases","volume":"26","author":"Honig","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ajg.2024.07.003_b0025","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1053\/j.gastro.2010.11.058","article-title":"The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease","volume":"140","author":"Lewis","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajg.2024.07.003_b0030","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1053\/j.gastro.2022.01.024","article-title":"Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities","volume":"162","author":"Plevris","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajg.2024.07.003_b0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.smim.2013.12.003","article-title":"Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development","volume":"26","author":"Waldner","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1016\/j.ajg.2024.07.003_b0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF02779504","article-title":"Significance of interleukin-6 in patients with inflammatory bowel disease","volume":"26","author":"Mitsuyama","year":"1991","journal-title":"Gastroenterol Jpn"},{"key":"10.1016\/j.ajg.2024.07.003_b0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10020-018-0047-0","article-title":"Serum amyloid A - a review","volume":"24","author":"Sack","year":"2018","journal-title":"Mol Med"},{"key":"10.1016\/j.ajg.2024.07.003_b0050","article-title":"Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker","volume":"11","author":"Sori\u0107 Hosman","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajg.2024.07.003_b0055","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MIB.0000000000000991","article-title":"Serum Amyloid A as a Surrogate Marker for Mucosal and Histologic Inflammation in Patients with Crohn\u2019s Disease","volume":"23","author":"Yarur","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ajg.2024.07.003_b0060","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ajg.2024.07.003_b0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.ajg.2024.07.003_b0070","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"315","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.ajg.2024.07.003_b0075","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.ajg.2024.07.003_b0080","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajg.2024.07.003_b0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1572-0241.2004.04071.x","article-title":"Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire","volume":"99","author":"Casellas","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ajg.2024.07.003_b0090","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/MIB.0000000000000341","article-title":"Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission","volume":"21","author":"Falvey","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ajg.2024.07.003_b0095","doi-asserted-by":"crossref","first-page":"e7780","DOI":"10.1097\/MD.0000000000007780","article-title":"Relationships of capsule endoscopy Lewis score with clinical disease activity indices, C-reactive protein, and small bowel transit time in pediatric and adult patients with small bowel Crohn\u2019s disease","volume":"96","author":"He","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.ajg.2024.07.003_b0100","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s10620-016-4180-8","article-title":"Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn\u2019s Disease Phenotypes","volume":"61","author":"Taleban","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ajg.2024.07.003_b0105","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cgh.2018.12.021","article-title":"Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review","volume":"17","author":"Restellini","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajg.2024.07.003_b0110","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajg.2024.07.003_b0115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.15403\/jgld.2014.1121.273.pti","article-title":"Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis","volume":"27","author":"Rokkas","year":"2018","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.ajg.2024.07.003_b0120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/1110-7782.182956","article-title":"Utility of fecal calprotectin as a discriminative biomarker between ulcerative colitis and irritable bowel syndrome and its ability to be used for the assessment of the remission stage of ulcerative colitis","volume":"28","author":"Elsaadany","year":"2016","journal-title":"Egypt J Intern Med"},{"key":"10.1016\/j.ajg.2024.07.003_b0125","doi-asserted-by":"crossref","unstructured":"Badawy AmiraM, Nouh MohamedAE, Ali AtefAE, El Halim EmadFA, Mohamed HosamI, El Ghany AymanMA. Calprotectin as a fecal marker for diagnosis and follow-up in patients with ulcerative colitis. Menoufia Medical Journal 2014;27:35. https:\/\/doi.org\/10.4103\/1110-2098.132726.","DOI":"10.4103\/1110-2098.132726"},{"key":"10.1016\/j.ajg.2024.07.003_b0130","first-page":"A85","article-title":"IDDF2019-ABS-0129 Optimal cut-off value of fecal calprotectin for the evaluation of inflammatory bowel disease: an unsolved issue? Clinical Gastroenterology, BMJ Publishing Group Ltd and British Society of","author":"Suchismita","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajg.2024.07.003_b0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jgh3.12068","article-title":"Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn\u2019s disease activity","volume":"2","author":"Zittan","year":"2018","journal-title":"JGH Open"},{"key":"10.1016\/j.ajg.2024.07.003_b0140","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3904\/kjim.2016.324","article-title":"The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity","volume":"34","author":"Lee","year":"2019","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.ajg.2024.07.003_b0145","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/ecco-jcc\/jjv150","article-title":"Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn\u2019s Disease","volume":"9","author":"Goutorbe","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ajg.2024.07.003_b0150","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4103\/1319-3767.182455","article-title":"Implementation of the simple endoscopic activity score in crohn\u2019s disease","volume":"22","author":"Koutroumpakis","year":"2016","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.ajg.2024.07.003_b0155","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/j.crohns.2013.05.005","article-title":"A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn\u2019s disease","volume":"7","author":"Lobat\u00f3n","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ajg.2024.07.003_b0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12876-016-0462-z","article-title":"Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis","volume":"16","author":"Kawashima","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ajg.2024.07.003_b0165","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.3748\/wjg.v23.i46.8235","article-title":"Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China","volume":"23","author":"Chen","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ajg.2024.07.003_b0170","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ajg.2009.545","article-title":"Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn\u2019s disease (SES-CD) than CRP, blood leukocytes, and the CDAI","volume":"105","author":"Schoepfer","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 2","key":"10.1016\/j.ajg.2024.07.003_b0175","first-page":"S262","article-title":"Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis","volume":"23","author":"Osada","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ajg.2024.07.003_b0180","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10620-013-2907-3","article-title":"Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis","volume":"59","author":"Yoon","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ajg.2024.07.003_b0185","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1586\/17474124.2014.893821","article-title":"C-reactive protein in Crohn\u2019s disease: how informative is it?","volume":"8","author":"Magro","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajg.2024.07.003_b0190","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/ibd.21933","article-title":"High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn\u2019s disease: a marker for patient classification?","volume":"18","author":"Kiss","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ajg.2024.07.003_b0195","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00054725-200409000-00026","article-title":"C-reactive protein as a marker for inflammatory bowel disease","volume":"10","author":"Vermeire","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ajg.2024.07.003_b0200","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12876-020-01229-8","article-title":"Serum amyloid A is a better predictive biomarker of mucosal healing than C-reactive protein in ulcerative colitis in clinical remission","volume":"20","author":"Wakai","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ajg.2024.07.003_b0205","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.dld.2017.12.010","article-title":"Serum amyloid A level correlated with endoscopic findings in patients with Crohn\u2019s disease-Possible biomarker for evaluating mucosal healing","volume":"50","author":"Ishihara","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ajg.2024.07.003_b0210","doi-asserted-by":"crossref","first-page":"e0233811","DOI":"10.1371\/journal.pone.0233811","article-title":"Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study","volume":"15","author":"Mavropoulou","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ajg.2024.07.003_b0215","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00384-018-3069-8","article-title":"Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases","volume":"33","author":"Nikolaus","year":"2018","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.ajg.2024.07.003_b0220","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/MIB.0b013e318280b19e","article-title":"Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn\u2019s disease, and ulcerative colitis patients","volume":"19","author":"Plevy","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ajg.2024.07.003_b0225","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12876-022-02304-y","article-title":"Combination of serological biomarkers and clinical features to predict mucosal healing in Crohn\u2019s disease: a multicenter cohort study","volume":"22","author":"Tang","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ajg.2024.07.003_b0230","doi-asserted-by":"crossref","first-page":"e00138","DOI":"10.14309\/ctg.0000000000000138","article-title":"Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease","volume":"11","author":"Mak","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.ajg.2024.07.003_b0235","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10620-016-4397-6","article-title":"High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score","volume":"62","author":"Bodelier","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ajg.2024.07.003_b0240","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ibd.20820","article-title":"Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease","volume":"15","author":"Quail","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ajg.2024.07.003_b0245","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"}],"container-title":["Arab Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197924000650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197924000650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T03:48:21Z","timestamp":1724471301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1687197924000650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1687197924000650"],"URL":"https:\/\/doi.org\/10.1016\/j.ajg.2024.07.003","relation":{},"ISSN":["1687-1979"],"issn-type":[{"value":"1687-1979","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of IBD disease activity by Interleukin-6 and serum amyloid A in relation with fecal calprotectin and endoscopic indices","name":"articletitle","label":"Article Title"},{"value":"Arab Journal of Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajg.2024.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}